drugset / Trial / NCT03005704

Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets

NCT03005704

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.

Timeline

Start
2017-01
Primary completion
2017-12
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 90 mg
Background Aspirin Small molecule 81 mg